Antidepressants as modulators of P2X7 receptor activity
Vitor Nascimento Vidal1, Guilherme Pegas Teixeira1, Juliana Vieira Faria2
1Postgraduate Program in Plant Biotechnology and Bioprocesses, Center of Health Sciences, Federal University of Rio de Janeiro, Carlos Chagas Filho Avenue 373, University City, Rio de Janeiro 21941-902 RJ, Brazil; Environmental Health Assessment and Promotion Laboratory, Oswaldo Cruz Institute, Brazil Avenue 4365, Rio de Janeiro 21040-900 RJ, Brazil.
Neuroscience
|December 19, 2025
Summary
Current depression treatments targeting neurotransmitters offer limited relief. This study reveals that blocking the P2X7 receptor, a key factor in neuroinflammation, shows antidepressant potential and may enhance existing therapies.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Depression affects over 300 million globally, with current treatments focusing on neurotransmitters yielding partial results.
- Neuroinflammation and elevated inflammatory cytokines are increasingly recognized as significant contributors to depression.
- The P2X7 receptor is implicated in depression, with its activation promoting a depressive phenotype and blockade showing antidepressant effects.
Purpose of the Study:
- To investigate the in-silico interaction between existing antidepressants and the allosteric site of the P2X7 receptor.
- To explore the potential of P2X7 receptor antagonists in combination with antidepressants for treating depression.
- To identify key amino acids involved in the interaction between antidepressants and the P2X7 receptor.
Main Methods:
- Utilized molecular docking simulations to analyze the binding of various antidepressants to the allosteric site of the P2X7 receptor.
- Evaluated the role of specific amino acids (TYR295 and PHE95) in the interaction.
- Reviewed existing literature on the anti-inflammatory activities of antidepressants and P2X7 receptor function.
Main Results:
- Molecular docking revealed that drugs containing TYR295 and PHE95 are crucial for effective interaction with the P2X7 receptor's allosteric site.
- The findings support the hypothesis that P2X7 receptor inhibition possesses antidepressant properties.
- Antidepressants demonstrated anti-inflammatory activity, reducing oxidative radicals and stimulating anti-inflammatory cytokines.
Conclusions:
- Blocking the P2X7 receptor offers a promising therapeutic strategy for depression, potentially addressing neuroinflammation.
- Combining current antidepressants with P2X7 receptor antagonists may provide a more effective treatment approach by attenuating neuroinflammation.
- Specific amino acid interactions highlight potential targets for novel antidepressant drug development.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
770
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
770
01:25Antidepressant Drugs: Overview
1.3K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.3K
01:21G-protein Coupled Receptors
131.3K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
131.3K
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.3K
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
477
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
477
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K